Amylyx Pharmaceuticals (NASDAQ:AMLX) CFO James Frates Sells 3,326 Shares

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) CFO James Frates sold 3,326 shares of Amylyx Pharmaceuticals stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $11.11, for a total transaction of $36,951.86. Following the transaction, the chief financial officer directly owned 177,104 shares of the company’s stock, valued at approximately $1,967,625.44. This trade represents a 1.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Amylyx Pharmaceuticals Trading Down 1.3%

AMLX stock opened at $11.83 on Friday. The business’s 50-day moving average is $13.05 and its 200 day moving average is $11.26. The stock has a market cap of $1.30 billion, a price-to-earnings ratio of -6.57 and a beta of -0.31. Amylyx Pharmaceuticals, Inc. has a 12-month low of $2.60 and a 12-month high of $16.96.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.06. As a group, equities analysts forecast that Amylyx Pharmaceuticals, Inc. will post -2.2 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the company. Aster Capital Management DIFC Ltd acquired a new stake in shares of Amylyx Pharmaceuticals in the third quarter valued at $48,000. California State Teachers Retirement System purchased a new position in Amylyx Pharmaceuticals during the 2nd quarter valued at about $28,000. Ameritas Investment Partners Inc. acquired a new position in Amylyx Pharmaceuticals in the 2nd quarter valued at about $45,000. BNP Paribas Financial Markets grew its position in Amylyx Pharmaceuticals by 433.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 7,267 shares of the company’s stock valued at $47,000 after acquiring an additional 5,904 shares in the last quarter. Finally, Legal & General Group Plc acquired a new stake in shares of Amylyx Pharmaceuticals during the second quarter worth about $47,000. 95.84% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. Guggenheim upped their price objective on shares of Amylyx Pharmaceuticals from $17.00 to $25.00 and gave the company a “buy” rating in a report on Monday, September 15th. Wall Street Zen downgraded shares of Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. Lifesci Capital upgraded Amylyx Pharmaceuticals to a “strong-buy” rating in a report on Monday, October 27th. Citigroup increased their price objective on Amylyx Pharmaceuticals from $12.00 to $20.00 and gave the stock a “buy” rating in a research report on Friday, October 17th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research report on Monday, December 29th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $17.25.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.